Analyzing Sentiment Trends for GE HealthCare Technologies (GEHC) Stocks

This morning we watched GE HealthCare Technologies drop -9.9% to a price of $80.12 per share. The Large-Cap Medical Electronics company is now trading -16.29% below its average target price of $95.71. Analysts have set target prices ranging from $86.0 to $110.0 per share for GE HealthCare Technologies, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 3.1%, and a short ratio of 3.6. The company's insiders own 6.93% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 72.1% of GE HealthCare Technologies's shares being owned by this investor type.

Institutions Invested in GE HealthCare Technologies

Date Reported Holder Percentage Shares Value
2023-12-31 General Electric Company 13% 61,581,302 $4,933,894,085
2023-12-31 Capital Research Global Investors 11% 51,344,719 $4,113,739,027
2023-12-31 Vanguard Group Inc 10% 44,411,594 $3,558,257,033
2023-12-31 Blackrock Inc. 6% 28,870,837 $2,313,131,539
2023-12-31 State Street Corporation 4% 18,583,969 $1,488,947,647
2023-12-31 Dodge & Cox Inc 4% 16,979,428 $1,360,391,817
2023-12-31 Price (T.Rowe) Associates Inc 3% 12,093,907 $968,963,862
2023-12-31 Geode Capital Management, LLC 2% 7,733,367 $619,597,385
2023-12-31 T. Rowe Price Investment Management, Inc. 2% 7,258,859 $581,579,803
2023-12-31 Hotchkis & Wiley Capital Management, LLC 1% 5,511,973 $441,619,291

Besides an analyst consensus of some upside potential, other market factors point to there being positive market sentiment on GE HealthCare Technologies.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS